comparemela.com

Page 3 - Jiangsu Hengrui Pharmaceuticals Co Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK Enters Agreement to Acquire Aiolos Bio

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway AIO-001 could redefine the standard-of-care.

GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio - GSK (NYSE:GSK)

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.